Hepatitis C virus in patients of chronic renal failure on regular hemodialysis

61 subjects were included in this study: 28 patients with chronic renal failure [CRF] on regular hemodialysis [H.D.] with history of blood transfusion [group I], 13 patients with CRF on regular H.D. And without history of blood transfusion [group II] and 20 normal control subjects [group III]. All subjects were examined clinically and subjected to sonographic examination of the liver, estimation of hepatitis B surface antigen [HBsAg] and estimation of hepatitis C virus antibodies [HCV Ab's]. Results showed that 19.5% of both groups I, II patients were seropositive for HCV Ab, 25% of group I patients were seropositive for HCV Ab's, while in group II, the prevalence was only 7.7%. Therefore, it can be concluded that blood transfusion is more serious as a risk factor in HCV infection than hemodialysis. Liver affection and liver enzymes elevations in patients on dialysis were not related to HCV infection but may be due to other causes

Results of treatment and survival of 231 patients with stage III bronchogenic carcinoma

Two hundred and thirty one patients with stage III Bronchogenic Carcinoma had been studied at NEMROCK [1974 1985]. 82% of patients had non small cell lung cancer, while 18% of patients had small cell lung cancer. 29% of patients received radiation therapy alone and 30% of patients received chemotherapy, while 41% of patients received combination of chemo and radiotherapy complete remission after treatment was obtained in 19.5% of patients, all of them received combined modality of treatment with a mean duration of response 10.5 +/- 11 months. There was a better 18 months survival for the patients received combined treatment modality as compared with other groups, and the difference was significant P < 0. 05]